Seagen reports third quarter 2021 financial results

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) reported financial results today for the third quarter and nine months ended september 30, 2021. the company also highlighted adcetris® (brentuximab vedotin), padcev® (enfortumab vedotin-ejfv), tukysa® (tucatinib) and tivdak™ (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its robust oncology pipeline. “we reported net product sales of approximately $1 billion for the year to date and $366
SGEN Ratings Summary
SGEN Quant Ranking